Rational design of potent sialidase-based inhibitors of influenza virus replication

Cited by (1,001)

Items 301–400 of 1,001

1. Peramivir (BCX-1812, RWJ-270201): potential new therapy for influenza
   Donald F. Smee, Robert W. Sidwell · 2002 · Expert Opinion on Investigational Drugs
2. New treatments for influenza
   Sailen Barik · 2012 · BMC Medicine
3. Carbocycles Related to Oseltamivir as Influenza Virus Group-1-Specific Neuraminidase Inhibitors. Binding to N1 Enzymes in the Context of Virus-like Particles
   Sankar Mohan, Sarah McAtamney, Thomas Haselhorst, Mark von Itzstein, Brian Mario Pinto · 2010 · Journal of Medicinal Chemistry
4. Dimeric Zanamivir Conjugates with Various Linking Groups Are Potent, Long-Lasting Inhibitors of Influenza Neuraminidase Including H5N1 Avian Influenza
   Simon J. F. Macdonald, Rachel Cameron, Derek A. Demaine, Rob J. Fenton, Graham Foster, David Gower, Jacqueline Hamblin, Stephanie Hamilton, Graham J. Hart, Alan P. Hill et al. · 2005 · Journal of Medicinal Chemistry
5. GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is a potent inhibitor of influenza virus in ferrets
   David Ryan, John R. Ticehurst, M H Dempsey · 1995 · Antimicrobial Agents and Chemotherapy
6. More-powerful virus inhibitors from structure-based analysis of HEV71 capsid-binding molecules
   Luigi De Colibus, Xiangxi Wang, John A. B. Spyrou, James T. Kelly, Jingshan Ren, Jonathan M. Grimes, Gerhard Puerstinger, Nicola J. Stonehouse, Thomas S. Walter, Zhongyu Hu et al. · 2014 · Nature Structural & Molecular Biology
7. Antivirals for influenza: Historical perspectives and lessons learned
   Frederick G. Hayden · 2006 · Antiviral Research
8. EFFICACY AND SAFETY OF THE NEURAMINIDASE INHIBITOR ZANAMIVIR IN THE TREATMENT OF INFLUENZAVIRUS INFECTIONS
   G. H Ayden, J Ohn J. T Reanor, M. F Leming, Yoshio OKI, K Arl G. N Icholson, M. B Ohnen · 1997
9. New small-molecule drug design strategies for fighting resistant influenza A
   Zuyuan Shen, Kaiyan Lou, Wei Wang · 2015 · Acta Pharmaceutica Sinica B
10. An infectious bat-derived chimeric influenza virus harbouring the entry machinery of an influenza A virus
    Mindaugas Juozapaitis, Étori Aguiar Moreira, Ignacio Mena, Sebastian Giese, David Riegger, Anne Pohlmann, Dirk W. Höper, Gert Zimmer, Martin Beer, Adolfo García‐Sastre et al. · 2014 · Nature Communications
11. Peramivir: A Novel Intravenous Neuraminidase Inhibitor for Treatment of Acute Influenza Infections
    Malak M. Alame, Elie Massaad, Hassan Zaraket · 2016 · Frontiers in Microbiology
12. Receptor Dependent Multidimensional QSAR for Modeling Drug - Receptor Interactions
    Jarosław Polański · 2009 · Current Medicinal Chemistry
13. Directed evolution of N-acetylneuraminic acid aldolase to catalyze enantiomeric aldol reactions
    Masaru Wada, Che‐Chang Hsu, Dirk Franke, Michael L. Mitchell, A. Heine, Ian A. Wilson, Chi‐Huey Wong · 2003 · Bioorganic & Medicinal Chemistry
14. Comparative Binding Energy (COMBINE) Analysis of Influenza Neuraminidase−Inhibitor Complexes
    Ting Wang, Rebecca C. Wade · 2001 · Journal of Medicinal Chemistry
15. Dry powder inhaler: influence of humidity on topology and adhesion studied by AFM
    Véronique Bérard, Éric Lesniewska, C Andrès, D Pertuy, C Laroche, Yvette Pourcelot · 2002 · International Journal of Pharmaceutics
16. Design and Synthesis of Benzoic Acid Derivatives as Influenza Neuraminidase Inhibitors Using Structure-Based Drug Design
    Pooran Chand, Yarlagadda S. Babu, Shanta Bantia, Naiming Chu, L. Brent Cole, Pravin L. Kotian, W. Graeme Laver, John A. Jr. Montgomery, Ved Prakash Pathak, Sandra L. Petty et al. · 1997 · Journal of Medicinal Chemistry
17. Efficacy of Novel Hemagglutinin-Neuraminidase Inhibitors BCX 2798 and BCX 2855 against Human Parainfluenza Viruses In Vitro and In Vivo
    Irina V. Alymova, Garry L. Taylor, Toru Takimoto, Tsu‐Hsing Lin, Pooran Chand, Y. Sudhakara Babu, Chenghong Li, Xiaoping Xiong, Allen Portner · 2004 · Antimicrobial Agents and Chemotherapy
18. Bacterial cell division proteins as antibiotic targets
    Tanneke den Blaauwen, José M. Andreu, Octavio Monasterio · 2014 · Bioorganic Chemistry
19. Synthesis of the potent influenza neuraminidase inhibitor 4-guanidino Neu5Ac2en. X-Ray molecular structure of 5-acetamido-4-amino-2,6-anhydro-3,4,5-trideoxy-D-erythro-L-gluco-nononic acid
    Malcolm Chandler, Mark J. Bamford, Richard Conroy, Brian Lamont, Bina Patel, Vipulkumar K. Patel, Ian P. Steeples, Richard Storer, Niall G. Weir, Michael Wright et al. · 1995 · Journal of the Chemical Society Perkin Transactions 1
20. Effective inhibition of influenza virus production in cultured cells by external guide sequences and ribonuclease P
    Debora Plehn-Dujowich, Sidney Altman · 1998 · Proceedings of the National Academy of Sciences
21. Kohlenhydratmimetika: ein neuer Lösungsansatz für das Problem der kohlenhydratvermittelten biologischen Erkennung
    P.S. Sears, Chi‐Huey Wong · 1999 · Angewandte Chemie
22. Understanding the Molecular Basis of Apert Syndrome
    Ibrahimi, Omar A., Chiu, Ernest S., McCarthy, Joseph G., Mohammadi, Moosa · 2005 · Plastic & Reconstructive Surgery
23. Influenza Virus: Small Molecule Therapeutics and Mechanisms of Antiviral Resistance
    Julianna Han, Jasmine T. Perez, Adam Schafer, Han Cheng, Norton P. Peet, Lijun Rong, Balaji Manicassamy · 2018 · Current Medicinal Chemistry
24. High-throughput Serum N-Glycomics: Method Comparison and Application to Study Rheumatoid Arthritis and Pregnancy-associated Changes
    Karli R. Reiding, Albert Bondt, René Hennig, Richard A. Gardner, Róisín O’Flaherty, Irena Trbojević‐Akmačić, Archana Shubhakar, Johanna M. W. Hazes, Udo Reichl, Daryl L. Fernandes et al. · 2018 · Molecular & Cellular Proteomics
25. Design, synthesis, and biological evaluation of human sialidase inhibitors. Part 1: Selective inhibitors of lysosomal sialidase (NEU1)
    Sadagopan Magesh, Setsuko Moriya, Tohru Suzuki, Taeko Miyagi, Hideharu Ishida, Makoto Kiso · 2007 · Bioorganic & Medicinal Chemistry Letters
26. Heads, stalks and everything else: how can antibodies eradicate influenza as a human disease?
    Karlynn E. Neu, Carole Henry, Patrick C. Wilson · 2016 · Current Opinion in Immunology
27. Emerging antiviral targets for influenza A virus
    Robert M. Krug, James M. Aramini · 2009 · Trends in Pharmacological Sciences
28. Penetration of GS4071, a novel influenza neuraminidase inhibitor, into rat bronchoalveolar lining fluid following oral administration of the prodrug GS4104
    Eugene J. Eisenberg, Alison M. Bidgood, Kenneth C. Cundy · 1997 · Antimicrobial Agents and Chemotherapy
29. An overview and future prospects of sialic acids
    Haiquan Yang, Liping Lu, Xianzhong Chen · 2020 · Biotechnology Advances
30. Carbohydrate–Protein Interactions
    Serge Pérez, Igor Tvaroška · 2014 · Advances in carbohydrate chemistry and biochemistry
31. Respiratory viral infections in the elderly
    John J. Treanor, Ann Regina Falsey · 1999 · Antiviral Research
32. The cysteine protease of Trypanosoma cruzi as a model for antiparasite drug design
    James Hobson McKerrow, Marisa E. McGrath, Juan Carlos Engel · 1995 · Parasitology Today
33. Monomeric inhibitors of influenza neuraminidase enhance the hemagglutination inhibition activities of polyacrylamides presenting multiple C-sialoside groups
    Seok Ki Choi, Mathai Mammen, George M. Whitesides · 1996 · Chemistry & Biology
34. The Pharmacokinetics and Tolerability of the Oral Neuraminidase Inhibitor Oseltamivir (Ro 64–0796/GS4104) in Healthy Adult and Elderly Volunteers
    Joseph W. Massarella, George Z. He, Albert E. Dorr, Keith A. Nieforth, Penelope Ward, Andy Brown · 2000 · The Journal of Clinical Pharmacology
35. Structural and Functional Basis of Resistance to Neuraminidase Inhibitors of Influenza B Viruses
    Aaron J. Oakley, Susan Barrett, Thomas S. Peat, Janet M. Newman, Victor A. Streltsov, Lynne J. Waddington, Takehiko Saito, Masato Tashiro, Jennifer L. McKimm‐Breschkin · 2010 · Journal of Medicinal Chemistry
36. Mode of action of the anti-influenza virus activity of plant flavonoid, 5,7,4′-trihydroxy-8-methoxyflavone, from the roots of Scutellaria baicalensis
    Takayuki Nagai, R. Moriguchi, Yujiro Suzuki, Tsuyoshi Tomimori, Haruki Yamada · 1995 · Antiviral Research
37. The Anti-Influenza Virus Agent 4-GU-DANA (Zanamivir) Inhibits Cell Fusion Mediated by Human Parainfluenza Virus and Influenza Virus HA
    Olga Greengard, Natalia Poltoratskaia, Evgenia Leikina, Joshua J. Zimmerberg, Anne Moscona · 2000 · Journal of Virology
38. A compendium of cyclic sugar amino acids and their carbocyclic and heterocyclic nitrogen analogues
    Martijn Risseeuw, Mark Overhand, George W. J. Fleet, Michela Iezzi Simone · 2013 · Amino Acids
39. Influenza Virus Resistance to Antiviral Therapy
    Erhard van der Vries, Martin Schutten, Pieter L. A. Fraaij, Charles A. Boucher, Albert D. M. E. Osterhaus · 2013 · Advances in pharmacology
40. Inhaled anti-infective chemotherapy for respiratory tract infections: Successes, challenges and the road ahead
    Tony Velkov, Nusaibah Abdul Rahim, Qi Tony Zhou, Hak‐Kim Chan, Jian Li · 2014 · Advanced Drug Delivery Reviews
41. Structure-based design of enzyme inhibitors and receptor ligands.
    Hugo Kubinyi · 1998 · PubMed
42. H1N1 2009 Pandemic Influenza Virus: Resistance of the I223R Neuraminidase Mutant Explained by Kinetic and Structural Analysis
    Erhard van der Vries, Patrick J. Collins, Sebastien G. Vachieri, Xiaoli Xiong, Junfeng Liu, P.A. Walker, Lesley F. Haire, Alan J Hay, Martin Schutten, Albert D. M. E. Osterhaus et al. · 2012 · PLoS Pathogens
43. A Reverse Genetics Study of Resistance to Neuraminidase Inhibitors in An Influenza A/H1N1 Virus
    Yacine Abed, Nathalie Goyette, Guy Boivin · 2004 · Antiviral Therapy
44. Fragment Informatics and Computational Fragment‐Based Drug Design: An Overview and Update
    Sheng, Chunquan, Zhang, Wannian · 2013 · Medicinal Research Reviews
45. Influenza treatment and prophylaxis with neuraminidase inhibitors: a review
    Mark Holodniy, Amanda Kamali · 2013 · Infection and Drug Resistance
46. Total Synthesis of A-315675: A Potent Inhibitor of Influenza Neuraminidase
    Stephen Hanessian, Malken Bayrakdarian, Xuehong Luo · 2002 · Journal of the American Chemical Society
47. Simple, Intuitive Calculations of Free Energy of Binding for Protein−Ligand Complexes. 2. Computational Titration and pH Effects in Molecular Models of Neuraminidase−Inhibitor Complexes
    Micaela Fornabaio, Pietro Cozzini, Andrea Mozzarelli, Donald J. Abraham, Glen E. Kellogg · 2003 · Journal of Medicinal Chemistry
48. Sensitivity of influenza viruses to zanamivir and oseltamivir: A study performed on viruses circulating in France prior to the introduction of neuraminidase inhibitors in clinical practice
    Olivier Ferraris, Nicole Kessler, Bruno Lina · 2005 · Antiviral Research
49. Conformational Selection of Glycomimetics at Enzyme Catalytic Sites: Experimental Demonstration of the Binding of Distinct High-Energy Distorted Conformations of C-, S-, and O-Glycosides by E. Coli β-Galactosidases
    Alicia García-Herrero, Esther Montero, José Muñoz-Muñoz, Juan F. Espinosa, Alejandro Vián, José Luis García, Juan Luis Asensio, Francisco Javier Cañada, Jesús Jiménez‐Barbero · 2002 · Journal of the American Chemical Society
50. Characterization of the sialidase molecular defects in sialidosis patients suggests the structural organization of the lysosomal multienzyme complex
    Kiven Erique Lukong · 2000 · Human Molecular Genetics
51. Protein-carbohydrate interactions
    Yves Bourne, Herman VAN TILBEURGH, Christian Cambillau · 1993 · Current Opinion in Structural Biology
52. Influenza Treatment: Limitations of Antiviral Therapy and Advantages of Drug Combination Therapy
    Sania Batool, Santosh Chokkakula, Min‐Suk Song · 2023 · Microorganisms
53. Molecular Basis of the Interaction for an Essential Subunit PA−PB1 in Influenza Virus RNA Polymerase: Insights from Molecular Dynamics Simulation and Free Energy Calculation
    Huanxiang Liu, Xiaojun Yao · 2009 · Molecular Pharmaceutics
54. Inhibitors of virus replication: recent developments and prospects
    Julia Magden, Leevi Kääriäinen, Tero Ahola · 2004 · Applied Microbiology and Biotechnology
55. Biochemistry and Function of Sialidases
    Megumi Saito, Robert K. Yu · 1995 · Springer eBooks
56. Influenza A virus transmission: contributing factors and clinical implications
    Jessica A. Belser, Taronna R. Maines, Terrence M. Tumpey, Jacqueline M. Katz · 2010 · Expert Reviews in Molecular Medicine
57. Microbial production of sialic acid and sialylated human milk oligosaccharides: Advances and perspectives
    Xiaolong Zhang, Yanfeng Liu, Long Liu, Jianghua Li, Guocheng Du, Jian Chen · 2019 · Biotechnology Advances
58. A comparison of the effectiveness of zanamivir and oseltamivir for the treatment of influenza A and B
    Naoki Kawai, Hideyuki Ikematsu, Norio Iwaki, Tetsunari Maeda, Hideo Kanazawa, Takashi Kawashima, Osame Tanaka, Satoshi Yamauchi, Kenichi Kawamura, Toru Nagai et al. · 2007 · Journal of Infection
59. Influenza Neuraminidase Inhibitors: Synthetic Approaches, Derivatives and Biological Activity
    Pedro Laborda, Suyan Wang, Josef Voglmeir · 2016 · Molecules
60. A validation study on the practical use of automated de novo design
    Martin Ståhl, Nikolay P. Todorov, Tim James, Harald Mauser, Hans-Joachim Boehm, Philip M. Dean · 2002 · Journal of Computer-Aided Molecular Design
61. A fully integrated protein crystallization platform for small-molecule drug discovery
    David J. Hosfield, John Palan, M.T. Hilgers, Daniel N. Scheibe, Duncan E. McRee, Raymond C. Stevens · 2003 · Journal of Structural Biology
62. Broad-spectrum antiviral effect ofAgrimonia pilosaextract on influenza viruses
    Woo-Jin Shin, Kwang Hee Lee, Myung Hwan Park, Baik Lin Seong · 2009 · Microbiology and Immunology
63. Sialic Acid Metabolism and Systemic Pasteurellosis
    Susan M. Steenbergen, Carol A. Lichtensteiger, Ruth E. Caughlan, Jackie Garfinkle, Troy E. Fuller, Eric R. Vimr · 2005 · Infection and Immunity
64. Modelling the performance of membrane nanofiltration—application to an industrially relevant separation
    W. Richard Bowen, Barrie Cassey, Peter Jones, Darren L. Oatley · 2004 · Journal of Membrane Science
65. Phase-Transfer-Catalyzed Alkylation of Guanidines by Alkyl Halides under Biphasic Conditions: A Convenient Protocol for the Synthesis of Highly Functionalized Guanidines
    David A. Powell, Philip D. Ramsden, Robert A. Batey · 2003 · The Journal of Organic Chemistry
66. Rapid Antiviral Effect of Inhaled Zanamivir in the Treatment of Naturally Occurring Influenza in Otherwise Healthy Adults
    Guy Boivin, Nathalie Goyette, Isabelle Hardy, Fred Y. Aoki, Anthony Wagner, Sylvie Trottier · 2000 · The Journal of Infectious Diseases
67. Mobility-Based Quantification of Multivalent Virus-Receptor Interactions: New Insights Into Influenza A Virus Binding Mode
    Matthias Müller, Daniel Christian Lauster, Helen H. K. Wildenauer, Andreas Herrmann, Stephan Block · 2019 · Nano Letters
68. Quick Access to Druglike Heterocycles: Facile Silver-Catalyzed One-Pot Multicomponent Synthesis of Aminoindolizines
    Yaguang Bai, Jing Zeng, Jimei Ma, Bala Kishan Gorityala, Xue‐Wei Liu · 2010 · Journal of Combinatorial Chemistry
69. Drugs against leishmaniasis: a synergy of technology and partnerships
    Antony J. Davis, Henry W. Murray, Emanuela Handman · 2003 · Trends in Parasitology
70. Neuraminidase Inhibitors as Anti-Influenza Virus Agents
    Choung U. Kim, Xiaowu Chen, Dirk B. Mendel · 1999 · Antiviral chemistry & chemotherapy
71. Synthesis and Antimetastatic Activity of l -Iduronic Acid-Type 1-N-Iminosugars
    Yoshio Nishimura, Takahiko Satoh, Hayamitsu Adachi, Shinichi Kondo, TOMIO TAKEUCHI, Masayuki AZETAKA, HARUMI FUKUYASU, Yumiko Iizuka · 1997 · Journal of Medicinal Chemistry
72. Development of gene therapy-based strategies for the treatment of eye diseases
    Piroska Elizabeth Rakoczy, Weiyong Shen, May C. Lai, Fabienne Rolling, Ian Jeffery Constable · 1999 · Drug Development Research
73. New Antivirals and Drug Resistance
    Peter M. Colman · 2009 · Annual Review of Biochemistry
74. Synthesis of α-Glucuronic Acid and Amide Derivatives in the Presence of a Participating 2-Acyl Protecting Group
    Manuela Tosin, Paul V. Murphy · 2002 · Organic Letters
75. Structure-based drug design
    Peter M. Colman · 1994 · Current Opinion in Structural Biology
76. Molecular studies of influenza B virus in the reverse genetics era
    D. Jackson, Ruth A. Elderfield, William Barclay · 2010 · Journal of General Virology
77. Influenza: vaccination and treatment
    Iain Stephenson, K. G. Nicholson · 2001 · European Respiratory Journal
78. Increasing Oral Absorption of Polar Neuraminidase Inhibitors: A Prodrug Transporter Approach Applied to Oseltamivir Analogue
    Deepak Gupta, Sheeba Varghese Gupta, Arik Dahan, Yasuhiro Tsume, John M. Hilfinger, Kyung‐Dall Lee, Gordon L. Amidon · 2012 · Molecular Pharmaceutics
79. Oseltamivir Is Adequately Absorbed Following Nasogastric Administration to Adult Patients with Severe H5N1 Influenza
    Walter R. J. Taylor, Bui Nghia Thinh, Giang Thuc Anh, Peter Horby, Heiman F. L. Wertheim, Niklas Lindegårdh, Menno D. de Jong, Kasia Stepniewska, Tran Thuy Hanh, Nguyễn Đức Hiền et al. · 2008 · PLoS ONE
80. Recent progress in structure-based anti-influenza drug design
    Juan Du, Timothy A. Cross, Huan‐Xiang Zhou · 2012 · Drug Discovery Today
81. Modulation of Disordered Proteins with a Focus on Neurodegenerative Diseases and Other Pathologies
    Anne H.S. Martinelli, Fernanda Cortez Lopes, Elisa Beatriz de Oliveira John, Célia R. Carlini, Rodrigo Ligabue‐Braun · 2019 · International Journal of Molecular Sciences
82. Stereoselective Total Synthesis of Racemic BCX-1812 (RWJ-270201) for the Development of Neuraminidase Inhibitors as Anti-influenza Agents
    Tomoko Mineno, Marvin J. Miller · 2003 · The Journal of Organic Chemistry
83. Binding Constants of Neuraminidase Inhibitors: An Investigation of the Linear Interaction Energy Method
    Ian D. Wall, Andrew R. Leach, David William Salt, Martyn Glenn Ford, Jonathan W. Essex · 1999 · Journal of Medicinal Chemistry
84. Integration of target discovery, drug discovery and drug delivery: A review on computational strategies
    Yorley Duarte, Valeria Márquez‐Miranda, Matthieu J. Miossec, Fernando Danilo González-Nilo · 2019 · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology
85. Anti‐influenza virus agents: Synthesis and mode of action
    Irene M. Lagoja, Erik De Clercq · 2006 · Medicinal Research Reviews
86. Computer-Aided Drug Design: An Innovative Tool for Modeling
    Pranita P. Kore, Madhavi M. Mutha, Rishikesh V. Antre, Rajesh J. Oswal, Sandip S. Kshirsagar · 2012 · Open Journal of Medicinal Chemistry
87. The High Resolution Structures of Free and Inhibitor-bound Trypanosoma rangeli Sialidase and its Comparison with T.cruziTrans-sialidase
    M.F. Amaya, Alejandro Buschiazzo, Tong Nguyen, Pedro M. Alzari · 2002 · Journal of Molecular Biology
88. Disentangling the Frames, the State of Research on the Alphavirus 6K and TF Proteins
    Jolene Ramsey, Suchetana Mukhopadhyay · 2017 · Viruses
89. Derived structure of the putative sialic acid transporter from Escherichia coli predicts a novel sugar permease domain
    J Martinez, S M Steenbergen, Eric R. Vimr · 1995 · Journal of Bacteriology
90. ‘Flu’ and structure-based drug design
    Rebecca C. Wade · 1997 · Structure
91. Microbial sialidases: does bigger always mean better?
    Eric R. Vimr · 1994 · Trends in Microbiology
92. Synthesis and evaluation of cyclosporine A-loaded polysialic acid–polycaprolactone micelles for rheumatoid arthritis
    David R. Wilson, Nan Zhang, Angela L. Silvers, Martin B. Forstner, Rebecca A. Bader · 2013 · European Journal of Pharmaceutical Sciences
93. Fragment‐based quantitative structure–activity relationship (FB‐QSAR) for fragment‐based drug design
    Qi‐Shi Du, Huang Ri-bo, Yu‐Tuo Wei, Zongwen Pang, Liqin Du, Kuo‐Chen Chou · 2008 · Journal of Computational Chemistry
94. PRO_SELECT: Combining structure-based drug design and combinatorial chemistry for rapid lead discovery. 1. Technology
    Christopher W. Murray, David E. Clark, T.R. Auton, Michael A. Firth, Jin Li, Richard A. Sykes, Bohdan Waszkowycz, David R. Westhead, Stephen C. Young · 1997 · Journal of Computer-Aided Molecular Design
95. Syntheses of C-3-Modified Sialylglycosides as Selective Inhibitors of Influenza Hemagglutinin and Neuraminidase
    Xue‐Long Sun, Yoshimi Kanie, Chao-tan Guo, Osamu Kanie, Yasuo Suzuki, Chi‐Huey Wong · 2000 · European Journal of Organic Chemistry
96. The In Silico Drug Discovery Toolbox: Applications in Lead Discovery and Optimization
    Agostino Bruno, Gabriele Costantino, Luca Sartori, Marco Radi · 2019 · Current Medicinal Chemistry
97. A Novel Class of Herbicides (Specific Inhibitors of Imidazoleglycerol Phosphate Dehydratase)
    Ichiro Mori, Raymonde Fonné‐Pfister, Si. Matsunaga, S. Tada, Y. Kimura, Genji Iwasaki, Jun’ichi Mano, M. Hatano, Toshihito Nakano, Si. Koizumi et al. · 1995 · PLANT PHYSIOLOGY
98. Pathogen-Host Protein-Carbohydrate Interactions as the Basis of Important Infections
    Karl‐Anders Karlsson · 2001 · Advances in experimental medicine and biology
99. In Vitro Selection and Characterisation of Influenza B/Beijing/1/87 Isolates with Altered Susceptibility to Zanamivir
    Jacqueline M. Barnett, A. Cadman, Fiona Burrell, Safia Madar, Andrew Lewis, Margaret Tisdale, Richard C. Bethell · 1999 · Virology
100. Molecular fields in drug discovery: getting old or reaching maturity?
     Simon Cross, Gabriele Cruciani · 2009 · Drug Discovery Today